Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and MRNA Vaccines and the Potential for Mass Vaccination During Pandemics

Overview

Journal Annu Rev Pharmacol Toxicol

Publisher Annual Reviews

Specialties Pharmacology
Toxicology

Date 2020 May 30

PMID 32466690

Citations 23

Authors

Jacob William Coffey

Gaurav Das Gaiha

Giovanni Traverso

Affiliations

Soon will be listed here.

Abstract

Oral vaccination enables pain-free and self-administrable vaccine delivery for rapid mass vaccination during pandemic outbreaks. Furthermore, it elicits systemic and mucosal immune responses. This protects against infection at mucosal surfaces, which may further enhance protection and minimize the spread of disease. The gastrointestinal (GI) tract presents a number of prospective mucosal inductive sites for vaccine targeting, including the oral cavity, stomach, and small intestine. However, currently available oral vaccines are effectively limited to live-attenuated and inactivated vaccines against enteric diseases. The GI tract poses a number of challenges,including degradative processes that digest biologics and mucosal barriers that limit their absorption. This review summarizes the approaches currently under development and future opportunities for oral vaccine delivery to established (intestinal) and relatively new (oral cavity, stomach) mucosal targets. Special consideration is given to recent advances in oral biologic delivery that offer promise as future platforms for the administration of oral vaccines.

Citing Articles

Revolutionizing Dentistry: Preclinical Insights and Future Applications of mRNA Vaccines in Dentistry-A Narrative Review.

Koren L, Koren A, Likic R, Katanec T Dent J (Basel). 2025; 13(2).

PMID: 39996953 PMC: 11854559. DOI: 10.3390/dj13020079.

Oral Yeast-Cell Microcapsule-Mediated DNA Vaccines Against Induce Effective Intestinal Immunity and Modulate Gut Microbiota.

Du L, Jia S, Zhang W, Cai C, Liu Y, Wang C Vaccines (Basel). 2025; 12(12.

PMID: 39772022 PMC: 11680129. DOI: 10.3390/vaccines12121360.

A novel oral vaccine delivery system for enhancing stability and immune protection: bacterium-like particle with functional coating.

De X, Gao M, Jia Z, Ren H, Liu R, Zhou X Front Microbiol. 2024; 15:1481514.

PMID: 39539708 PMC: 11557395. DOI: 10.3389/fmicb.2024.1481514.

Recent development of oral vaccines (Review).

Liu Y, Lam D, Luan M, Zheng W, Ai H Exp Ther Med. 2024; 27(5):223.

PMID: 38590568 PMC: 11000446. DOI: 10.3892/etm.2024.12511.

Construction and Evaluation of an Efficient Live Attenuated Choleraesuis Vaccine and Its Ability as a Vaccine Carrier to Deliver Heterologous Antigens.

Bian X, Chen J, Chen X, Liu C, Ding J, Li M Vaccines (Basel). 2024; 12(3).

PMID: 38543883 PMC: 10974600. DOI: 10.3390/vaccines12030249.

References

Albu D, Jones-Trower A, Woron A, Stellrecht K, Broder C, Metzger D . Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol. 2003; 77(10):5589-97. PMC: 154022. DOI: 10.1128/jvi.77.10.5589-5597.2003. View

Roland K, Brenneman K . Salmonella as a vaccine delivery vehicle. Expert Rev Vaccines. 2013; 12(9):1033-45. PMC: 3956298. DOI: 10.1586/14760584.2013.825454. View

Eldridge J, Meulbroek J, Staas J, Tice T, Gilley R . Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol. 1989; 251:191-202. DOI: 10.1007/978-1-4757-2046-4_18. View

Morales J, Fathe K, Brunaugh A, Ferrati S, Li S, Montenegro-Nicolini M . Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes. AAPS J. 2017; 19(3):652-668. DOI: 10.1208/s12248-017-0054-z. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Lubeck M, Davis A, Chengalvala M, Natuk R, MORIN J, Mason B . Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989; 86(17):6763-7. PMC: 297926. DOI: 10.1073/pnas.86.17.6763. View

Chen X, Fernando G, Crichton M, Flaim C, Yukiko S, Fairmaid E . Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release. 2011; 152(3):349-55. DOI: 10.1016/j.jconrel.2011.02.026. View

Draper S, Heeney J . Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2009; 8(1):62-73. DOI: 10.1038/nrmicro2240. View

Summerton N, Welch R, Bondoc L, Yang H, Pleune B, Ramachandran N . Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine. 2009; 28(5):1404-11. PMC: 2814929. DOI: 10.1016/j.vaccine.2009.10.147. View

10.

Jiang T, Singh B, Li H, Kim Y, Kang S, Nah J . Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials. 2013; 35(7):2365-73. DOI: 10.1016/j.biomaterials.2013.11.073. View

11.

Hovav A . Dendritic cells of the oral mucosa. Mucosal Immunol. 2013; 7(1):27-37. DOI: 10.1038/mi.2013.42. View

12.

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

13.

Delgado A, Lavelle E, Hartshorne M, Davis S . PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine. 1999; 17(22):2927-38. DOI: 10.1016/s0264-410x(99)00140-1. View

14.

Howard K, Li X, Somavarapu S, Singh J, Green N, Atuah K . Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim Biophys Acta. 2004; 1674(2):149-57. DOI: 10.1016/j.bbagen.2004.06.009. View

15.

Anselmo A, Gokarn Y, Mitragotri S . Non-invasive delivery strategies for biologics. Nat Rev Drug Discov. 2018; 18(1):19-40. DOI: 10.1038/nrd.2018.183. View

16.

Wang T, Jiang H, Zhao Q, Wang S, Zou M, Cheng G . Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. Int J Pharm. 2012; 436(1-2):351-8. DOI: 10.1016/j.ijpharm.2012.06.028. View

17.

Mazzoni M, Bosi P, De Sordi N, Lalatta-Costerbosa G . Distribution, organization and innervation of gastric MALT in conventional piglet. J Anat. 2011; 219(5):611-21. PMC: 3222840. DOI: 10.1111/j.1469-7580.2011.01415.x. View

18.

Crichton M, Muller D, Depelsenaire A, Pearson F, Wei J, Coffey J . The changing shape of vaccination: improving immune responses through geometrical variations of a microdevice for immunization. Sci Rep. 2016; 6:27217. PMC: 4890175. DOI: 10.1038/srep27217. View

19.

Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters R . Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med. 2012; 18(8):1291-6. PMC: 3475749. DOI: 10.1038/nm.2866. View

20.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A . Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen,.... Vaccine. 2013; 31(20):2457-64. DOI: 10.1016/j.vaccine.2013.03.027. View